Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Karyopharm Therapeutics (KPTI) Change in Accured Expenses (2016 - 2025)

Karyopharm Therapeutics (KPTI) has disclosed Change in Accured Expenses for 14 consecutive years, with $1.4 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Change in Accured Expenses fell 77.67% year-over-year to $1.4 million, compared with a TTM value of $19.1 million through Dec 2025, up 353.77%, and an annual FY2025 reading of $19.1 million, up 353.77% over the prior year.
  • Change in Accured Expenses was $1.4 million for Q4 2025 at Karyopharm Therapeutics, down from $9.5 million in the prior quarter.
  • Across five years, Change in Accured Expenses topped out at $12.1 million in Q3 2021 and bottomed at -$9.4 million in Q1 2023.
  • Average Change in Accured Expenses over 5 years is $1.7 million, with a median of $2.3 million recorded in 2022.
  • The sharpest move saw Change in Accured Expenses plummeted 373.51% in 2022, then surged 14957.89% in 2025.
  • Year by year, Change in Accured Expenses stood at $3.7 million in 2021, then plummeted by 43.34% to $2.1 million in 2022, then surged by 129.16% to $4.8 million in 2023, then soared by 35.08% to $6.5 million in 2024, then crashed by 77.67% to $1.4 million in 2025.
  • Business Quant data shows Change in Accured Expenses for KPTI at $1.4 million in Q4 2025, $9.5 million in Q3 2025, and $8.6 million in Q2 2025.